JP2024536146A5 - - Google Patents
Info
- Publication number
- JP2024536146A5 JP2024536146A5 JP2024519313A JP2024519313A JP2024536146A5 JP 2024536146 A5 JP2024536146 A5 JP 2024536146A5 JP 2024519313 A JP2024519313 A JP 2024519313A JP 2024519313 A JP2024519313 A JP 2024519313A JP 2024536146 A5 JP2024536146 A5 JP 2024536146A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- compound according
- modified
- nucleic acid
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251562P | 2021-10-01 | 2021-10-01 | |
| US63/251,562 | 2021-10-01 | ||
| US202163287960P | 2021-12-09 | 2021-12-09 | |
| US63/287,960 | 2021-12-09 | ||
| PCT/US2022/077389 WO2023056446A1 (en) | 2021-10-01 | 2022-09-30 | Angiotensinogen-modulating compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536146A JP2024536146A (ja) | 2024-10-04 |
| JP2024536146A5 true JP2024536146A5 (enExample) | 2025-10-07 |
Family
ID=85783681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519313A Pending JP2024536146A (ja) | 2021-10-01 | 2022-09-30 | アンジオテンシノーゲンを調節する組成物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240401045A1 (enExample) |
| EP (1) | EP4408525A4 (enExample) |
| JP (1) | JP2024536146A (enExample) |
| KR (1) | KR20240099244A (enExample) |
| AU (1) | AU2022355198A1 (enExample) |
| CA (1) | CA3233330A1 (enExample) |
| WO (1) | WO2023056446A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| AU2022396536A1 (en) * | 2021-11-24 | 2024-06-06 | Adarx Pharmaceuticals, Inc. | Complement factor b-modulating compositions and methods of use thereof |
| AU2024301682A1 (en) * | 2023-07-21 | 2026-01-22 | Adarx Pharmaceuticals, Inc. | Coagulation factor xi-modulating compositions and methods of use thereof |
| WO2025087237A1 (zh) * | 2023-10-23 | 2025-05-01 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015264038B2 (en) * | 2014-05-22 | 2021-02-11 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (AGT) iRNA compositions and methods of use thereof |
| CN113817735A (zh) * | 2015-10-08 | 2021-12-21 | Ionis制药公司 | 用于调节血管紧张素原表达的化合物和方法 |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| JP2024513972A (ja) * | 2021-04-13 | 2024-03-27 | エーダーエックス ファーマシューティカルズ， インコーポレイテッド | Ｒｎａサイレンシング剤および使用方法 |
| US20240041913A1 (en) * | 2022-04-01 | 2024-02-08 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
-
2022
- 2022-09-30 US US18/697,165 patent/US20240401045A1/en active Pending
- 2022-09-30 CA CA3233330A patent/CA3233330A1/en active Pending
- 2022-09-30 KR KR1020247014615A patent/KR20240099244A/ko active Pending
- 2022-09-30 EP EP22877626.6A patent/EP4408525A4/en active Pending
- 2022-09-30 WO PCT/US2022/077389 patent/WO2023056446A1/en not_active Ceased
- 2022-09-30 JP JP2024519313A patent/JP2024536146A/ja active Pending
- 2022-09-30 AU AU2022355198A patent/AU2022355198A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024536146A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2023536974A5 (enExample) | ||
| JP2025165976A5 (enExample) | ||
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2021074010A5 (enExample) | ||
| US7709449B2 (en) | Nucleic acid-based compounds and methods of use thereof | |
| JP2018199700A5 (enExample) | ||
| JP2025511183A5 (enExample) | ||
| JP2024541771A5 (enExample) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2024535888A5 (enExample) | ||
| JPH11511436A (ja) | 化学化合物、それらの調製及び使用 | |
| EA022429B1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| JP2020511155A5 (enExample) | ||
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| JP2009539765A (ja) | Ａ２ａｒアゴニストとしての置換されたアリールピペリジニルアルキニルアデノシン | |
| JP2024543496A5 (enExample) | ||
| IL277970B1 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugate groups for use in treating end stage renal disease, chronic kidney disease, and coronary artery disease | |
| JP2021090458A5 (enExample) | ||
| JP2024539629A5 (enExample) | ||
| JP2022520986A5 (enExample) | ||
| JP2024534502A5 (enExample) | ||
| JP2023519518A5 (enExample) | ||
| JP2006141402A5 (enExample) |